Novel ways to attack inflammation in thyroid eye disease

References

• Weetman AP. Graves’ disease. N. Engl. J. Med.343, 1236–1248 (2000).
   PubMed Web of Science ®Google Scholar
• Brent GA. Clinical practice: Graves’ disease. N. Engl. J. Med.358, 2594–2605 (2008).
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology103, 958–962 (1996).
   PubMed Web of Science ®Google Scholar
• Adams DD, Purves HD. Abnormal responses in the assay of thyrotropins. Proc. Univ. Otago Med. Sch.34, 11–12 (1956).
   Google Scholar
• Meek JC, Jones AE, Lewis UJ, Vanderlaan WP. Characterization of the long-acting thyroid stimulator of Graves’ disease. Proc. Natl Acad. Sci. USA52, 342–349 (1964).
   PubMed Web of Science ®Google Scholar
• Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long-acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J. Clin. Endocrinol. Metab.24, 1005–1028 (1964).
   PubMed Web of Science ®Google Scholar
• Pastan I, Roth J, Macchia V. Binding of hormone to tissue: the first step in polypeptide hormone action. Proc. Natl Acad. Sci. USA56, 1802–1809 (1966).
   PubMed Web of Science ®Google Scholar
• Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid12, 855–860 (2002).
   PubMed Web of Science ®Google Scholar
• Rundle FF, Wilson CW. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin. Sci.5, 177–194 (1945).
   PubMed Web of Science ®Google Scholar
• Thornton J, Kelly SP, Harrison RA, Edwards R. Cigarette smoking and thyroid eye disease: a systematic review. Eye21, 1135–1145 (2007).
   PubMed Web of Science ®Google Scholar
• Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, Van Der Gaag R. Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy. Arch. Intern. Med.150, 1098–1101 (1990).
   PubMedGoogle Scholar
• Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur. J. Endocrinol.130, 494–497 (1994).
   PubMed Web of Science ®Google Scholar
• Dickinson J, Perros P. Thyroid-associated orbitopathy: who and how to treat. Endocrinol. Metab. Clin. North Am.38, 373–388 (2009).
   PubMed Web of Science ®Google Scholar
• Schotthoefer EO, Wallace DK. Strabismus associated with thyroid eye disease. Curr. Opin. Ophthalmol.18, 361–365 (2007).
   PubMed Web of Science ®Google Scholar
• Ben Simon GJ, Mansury AM, Schwarcz RM, Lee S, McCann JD, Goldberg RA. Simultaneous orbital decompression and correction of upper eyelid retraction versus staged procedures in thyroid-related orbitopathy. Ophthalmology112, 923–932 (2005).
   PubMed Web of Science ®Google Scholar
• Kikkawa DO, Pornpanich K, Cruz RC, Levi L, Granet DB. Graded orbital decompression based on severity of proptosis. Ophthalmology109, 1219–1224 (2002).
   PubMed Web of Science ®Google Scholar
• Pappa A, Calder V, Aijan R. Analysis of extraocular muscle-infiltrating T cells in thyroid-associated ophthalmopathy (TAO). Clin. Exp. Immunol.109, 362–369 (1997).
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Quadbeck B, Tews S et al. Thyroid associated ophthalmopathy: evidence for CD4(+) γδ T cells, de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells, and loss of γδ and αβ T cell receptor expression. Br. J. Ophthalmol.88, 803–808 (2004).
   PubMed Web of Science ®Google Scholar
• Wakelkamp IM, Gerding MN, Van Der Meer JW, Prummel MF, Wiersinga WM. Both Th1- and Th2-derived cytokines in serum are elevated in Graves’ ophthalmopathy. Clin. Exp. Immunol.121, 453–457 (2000).
   PubMed Web of Science ®Google Scholar
• Yang D, Hiromatsu Y, Hoshino T, Inoue Y, Itoh K, Nonaka K. Dominant infiltration of T(h)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid9, 305–310 (1999).
   PubMed Web of Science ®Google Scholar
• McLachlan SM, Prummel MF, Rapoport B. Cell-mediated or humoral immunity in Graves’ ophthalmopathy? Profiles of T-cell cytokines amplified by polymerase chain reaction from orbital tissue. J. Clin. Endocrinol. Metab.78, 1070–1074 (1994).
   PubMed Web of Science ®Google Scholar
• Paul W. Fundamental Immunology(Fifth Edition). Lippincott Williams and Wilkins, PA, USA (2003).
   Google Scholar
• Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab.88, 4246–4250 (2003).
   PubMed Web of Science ®Google Scholar
• Hiromatsu Y, Yang D, Bednarczuk T, Miyake I, Nonaka K, Inoue Y. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.85, 1194–1199 (2000).
   PubMed Web of Science ®Google Scholar
• Masteller EL, Warner MR, Tang Q et al. Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from non-obese mice. J. Immunol.175, 3053–3059 (2005).
   PubMed Web of Science ®Google Scholar
• Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat. Rev. Immunol.5, 343–349 (2005).
   PubMed Web of Science ®Google Scholar
• Kohm AP, Williams JS, Bickford AL et al. Treatment with nonmitogenic anti-CD3 monoclonal antibody induces CD4+ T cell unresponsiveness and functional reversal of established experimental autoimmune encephalomyelitis. J. Immunol.174, 4525–4534 (2005).
   PubMed Web of Science ®Google Scholar
• Earle KE, Tang Q, Zhou X et al.In vitro expanded human CD4+ CD25+ regulatory T cells suppress effector T cell proliferation. Clin. Immunol.115, 3–9 (2005).
   PubMed Web of Science ®Google Scholar
• Tang Q, Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol. Rev.212, 217–237 (2006).
   PubMed Web of Science ®Google Scholar
• Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat. Rev. Immunol.7, 622–632 (2007).
   PubMed Web of Science ®Google Scholar
• Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol.177, 1451–1459 (2006).
   PubMed Web of Science ®Google Scholar
• Sagoo P, Lombardi G, Lechler RI. Regulatory T cells as therapeutic cells. Curr. Opin. Organ Transplant.13, 645–653 (2008).
   PubMed Web of Science ®Google Scholar
• Pichurin P, Aliesky H, Chen CR, Nagayama Y, Rapoport B, McLachlan SM. Thyrotrophin receptor-specific memory T cell responses require normal B cells in a murine model of Graves’ disease. Clin. Exp. Immunol.134, 396–402 (2003).
   PubMed Web of Science ®Google Scholar
• Naik V, Khadavi N, Naik MN et al. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid18, 967–971 (2008).
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C3B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood90, 2188–2195 (1997).
   PubMed Web of Science ®Google Scholar
• Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology52, 1701–1704 (1999).
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology40, 205–211 (2001).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur. J. Endocrinol.154, 511–517 (2006).
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Hasselbach HC, Hegedus L. Treatment-resistant severe, active Graves’ ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid16, 709–710 (2006).
   PubMed Web of Science ®Google Scholar
• El Fassi D, Nielsen CH, Bonnema SJ, Hasselbach HC, Hegedus L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J. Clin. Endocrinol. Metab.92, 1769–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol.156, 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Khanna D, Chong KK, Afifiyan NF et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.95, 430–438 (2010).
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Bahn RS. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves’ ophthalmopathy. Eur. J. Clin. Invest.23, 10–17 (1993).
   PubMed Web of Science ®Google Scholar
• Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit24, 117–119 (2005).
   PubMedGoogle Scholar
• Paridaens D, Van Den Bosch WA, Van Der Loos TL, Krenning EP, Van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye19, 1286–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients. Clin. Endocrinol.58, 280–287 (2003).
   PubMed Web of Science ®Google Scholar
• Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J. Clin. Endocrinol. Metab.82, 2003–2005 (1997).
   PubMed Web of Science ®Google Scholar
• Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves’ disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity36, 409–415 (2003).
   PubMed Web of Science ®Google Scholar
• Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J. Immunol.170, 6348–6354 (2003).
   PubMed Web of Science ®Google Scholar
• Tsui S, Naik V, Hoa N et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J. Immunol.181, 4397–4405 (2008).
   PubMed Web of Science ®Google Scholar
• Hopkins A, Crowe PJ, Yang JL. Effect of type 1 insulin-like growth factor receptor targeted therapy on chemotherapy in human cancer and the mechanisms involved. J. Cancer Res. Clin. Oncol.136, 639–650 (2010).
   PubMed Web of Science ®Google Scholar
• Cao HJ, Han R, Smith TJ. Robust induction of PGHS-2 by IL-1 in orbital fibroblasts results from low levels of IL-1 receptor antagonist expression. Am. J. Physiol. Cell Physiol.284, 1429–1437 (2003).
   Google Scholar
• Galligan CL, Siminovitch KA, Keystone EC, Bykerk V, Perez OD, Fish EN. Fibrocyte activation in rheumatoid arthritis. Rheumatology49, 640–651 (2010).
   PubMed Web of Science ®Google Scholar
• Strieter RM, Keeley EC, Hughes MA, Burdick MD, Mehrad B. The role of circulating mesenchymal progenitor cells (fibrocytes) in the pathogenesis of pulmonary fibrosis. J. Leukoc. Biol.86, 1111–1118 (2009).
   PubMed Web of Science ®Google Scholar
• Sakai N, Wada T, Matsushima K et al. The renin–angiotensin system contributes to renal fibrosis through regulation of fibrocytes. J. Hypertens.26, 780–790 (2008).
   PubMed Web of Science ®Google Scholar
• Douglas RS, Afifiyan NF, Hwang CJ et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab.95, 430–438 (2010).
   PubMed Web of Science ®Google Scholar
• Hwang CJ, Afifiyan N, Sand D et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Invest. Ophthalmol. Vis. Sci.50, 2262–2269 (2009).
   PubMed Web of Science ®Google Scholar
• Nanji SA, Hancock WW, Luo B et al. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse. Diabetes55, 27–33 (2006).
   PubMed Web of Science ®Google Scholar
• Liu Z, Geboes K, Colpaert S et al. Prevention of experimental colitis in SCID mice reconstituted with CD45RBhigh CD4+ T cells by blocking the CD40–CD154 interactions. J. Immunol.164, 6005–6014 (2000).
   PubMed Web of Science ®Google Scholar